Market Research Logo

Generics in the Netherlands

Generics in the Netherlands

Summary

Generics in the Netherlands industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the Netherlands generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Key Highlights

  • For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
  • The Dutch generics market had total revenues of $1.1bn in 2017, representing a compound annual growth rate (CAGR) of 2% between 2013 and 2017.
  • Market consumption volume increased with a CAGR of 2.1% between 2013 and 2017, to reach a total of 76.1% in 2017.
  • The Dutch government is actively stopping companies raising pharmaceutical prices in conjunction with the Belgian government, which is slowing generics market growth, as well as in the wider pharmaceutical industry.
Scope
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in the Netherlands
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in the Netherlands
  • Leading company profiles reveal details of key generics market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Netherlands generics market with five year forecasts by both value and volume
Reasons to buy
  • What was the size of the Netherlands generics market by value in 2017?
  • What will be the size of the Netherlands generics market in 2022?
  • What factors are affecting the strength of competition in the Netherlands generics market?
  • How has the market performed over the last five years?
  • How large is the Netherlands’s generics market in relation to its regional counterparts?


Executive Summary
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Mylan N.V.
Novartis AG
Sanofi SA
Teva Pharmaceutical Industries Limited
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine
List of Tables
Table 1: Netherlands generics market value: $ million, 2013-17
Table 2: Netherlands generics market volume: % of total pharma, 2013-17
Table 3: Netherlands generics market geography segmentation: $ million, 2017
Table 4: Netherlands generics market value forecast: $ million, 2017-22
Table 5: Netherlands generics market volume forecast: % of total pharma, 2017-22
Table 6: Mylan N.V.: key facts
Table 7: Mylan N.V.: key financials ($)
Table 8: Mylan N.V.: key financial ratios
Table 9: Novartis AG: key facts
Table 10: Novartis AG: key financials ($)
Table 11: Novartis AG: key financial ratios
Table 12: Sanofi SA: key facts
Table 13: Sanofi SA: key financials ($)
Table 14: Sanofi SA: key financials (€)
Table 15: Sanofi SA: key financial ratios
Table 16: Teva Pharmaceutical Industries Limited: key facts
Table 17: Teva Pharmaceutical Industries Limited: key financials ($)
Table 18: Teva Pharmaceutical Industries Limited: key financial ratios
Table 19: Netherlands size of population (million), 2013-17
Table 20: Netherlands gdp (constant 2005 prices, $ billion), 2013-17
Table 21: Netherlands gdp (current prices, $ billion), 2013-17
Table 22: Netherlands inflation, 2013-17
Table 23: Netherlands consumer price index (absolute), 2013-17
Table 24: Netherlands exchange rate, 2013-17
List of Figures
Figure 1: Netherlands generics market value: $ million, 2013-17
Figure 2: Netherlands generics market volume: % of total pharma, 2013-17
Figure 3: Netherlands generics market geography segmentation: % share, by value, 2017
Figure 4: Netherlands generics market value forecast: $ million, 2017-22
Figure 5: Netherlands generics market volume forecast: % of total pharma, 2017-22
Figure 6: Forces driving competition in the generics market in the Netherlands, 2017
Figure 7: Drivers of buyer power in the generics market in the Netherlands, 2017
Figure 8: Drivers of supplier power in the generics market in the Netherlands, 2017
Figure 9: Factors influencing the likelihood of new entrants in the generics market in the Netherlands, 2017
Figure 10: Factors influencing the threat of substitutes in the generics market in the Netherlands, 2017
Figure 11: Drivers of degree of rivalry in the generics market in the Netherlands, 2017
Figure 12: Mylan N.V.: revenues & profitability
Figure 13: Mylan N.V.: assets & liabilities
Figure 14: Novartis AG: revenues & profitability
Figure 15: Novartis AG: assets & liabilities
Figure 16: Sanofi SA: revenues & profitability
Figure 17: Sanofi SA: assets & liabilities
Figure 18: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 19: Teva Pharmaceutical Industries Limited: assets & liabilities

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report